JDD April 2025 Issue Highlights: Innovation, Inclusion & Insight in Dermatology
This month’s Journal of Drugs in Dermatology issue is packed with groundbreaking studies and real-world insights spanning across age groups, skin types, and therapeutic categories. From improving dermatoporosis in older adults to exploring an acne management algorithm that smartly integrates acneceuticals, the April Editor’s Picks reflect dermatology’s evolving landscape.
Highlights include …
This month’s Journal of Drugs in Dermatology issue is packed with groundbreaking studies and real-world insights spanning across age groups, skin types, and therapeutic categories. From improving dermatoporosis in older adults to exploring an acne management algorithm that smartly integrates acneceuticals, the April Editor’s Picks reflect dermatology’s evolving landscape.
Highlights include … Continue reading "JDD April 2025 Issue Highlights: Innovation, Inclusion & Insight in Dermatology"
Hidradenitis Suppurativa (HS) is a challenging dermatological condition characterized by painful, recurrent, and often disfiguring skin lesions. In this article, we will explore the expert insights of Dr. Ginette Okoye, Professor and Chair of the Howard University Department of Dermatology, as she discussed her approach to and experience with treating patients with HS at the 2023 Skin of Color Upd … 
Botulinum toxin is a safe and potentially effective treatment alternative in hidradenitis suppurativa (HS) patients who are resistant to standard therapies, according to the authors of a systematic review published in the Journal of Drugs in Dermatology.
How does this review add to the conversation about new treatments for HS? In which HS patients might dermatologists consider botulinum toxin as … 